The Burlington-based biotechnology firm is developing C-1101 as a non-opioid, platelet-derived biologic intended to move beyond symptom management by addressing the underlying biology of nerve injury. By delivering cytokines, growth factors, and matrix proteins directly to the site of irritation via epidural injection, the therapy aims to stimulate cellular repair. Consano Bio Chief Executive Officer Andrew Hall noted that the designation reflects the significant unmet medical need for patients suffering from persistent, debilitating pain.

LSR accounts for roughly $135 billion in annual U.S. healthcare spending and is frequently associated with depression and suicidal ideation. Consano Bio is currently testing the candidate in a multi-center, randomized, double-blind Phase 1 study, designated C-1101-101. Following the recent clearance of its Investigational New Drug application in July 2026, the company is expanding its clinical trials from Australia into the United States to evaluate the efficacy of the treatment across three dose-escalation cohorts.